Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC.
J Clin Oncol. 2009 Oct 1;27(28):4718-26. Epub 2009 Aug 31.PMID: 19720910 [PubMed - indexed for MEDLINE]Related articles